Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.94 |
| ▸ | DNM1 | Q05193 | 11/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.71 |
| ▸ | RAD52 | P43351 | 2/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.71 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL115547 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL8076347 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL18141480 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL783595 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL2980848 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL5603636 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL25287222 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL5804789 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL22206819 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL22436441 | 1.00 | HTT (0.94) | HTTDNM1KMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528601-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PULMONARY HYPERTENSION | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092690-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF PULMONARY HYPERTENSION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2011-08-04 | — | — | WO | claimed |
| WO-2010009146-A1 | NANOCLUSTERS FOR DELIVERY OF POORLY WATER SOLUBLE DRUG NANOPARTICLES | UNIVERSITY OF KANSAS (US) | 2010-01-21 | — | — | WO | claimed |
| US-20080279949-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL LTD. | 2008-11-13 | — | — | US | claimed |
| US-5399363-A | IV administration for insoluble medicaments | EASTMAN KODAK COMPANY (US) | 1995-03-21 | — | — | US | claimed |
| EP-0577215-A1 | Surface modified anticancer nanoparticles | NanoSystems L.L.C. (US) | 1994-01-05 | — | — | EP | claimed |
| US-20260060986-A1 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-05 | — | — | US | disclosed |
| US-12472184-B2 | Dosing regimens associated with extended release paliperidone injectable formulations | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250275967-A1 | FREEZE DRIED COMPOSITIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2025-09-04 | — | — | US | disclosed |
| US-20250268896-A1 | LIQUID COMPOSITIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2025-08-28 | — | — | US | disclosed |
| US-20250161456-A1 | FORMULATION/COMPOSITIONS COMPRISING IBRUTINIB | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-22 | — | — | US | disclosed |
| CN-119968203-A | Long-acting formulations | 詹森药业有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4511007-A1 | FREEZE DRIED COMPOSITIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2025-02-26 | — | — | EP | disclosed |
| EP-0577215-B1 | Process for obtaining surface modified anticancer nanoparticles | NANOSYSTEMS LLC (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999025354-A2 | AQUEOUS SUSPENSIONS OF SUBMICRON 9-HYDROXYRISPERIDONE FATTY ACID ESTERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-05-27 | — | — | WO | disclosed |
| EP-0805678-A1 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996020698-A2 | SURFACE-MODIFIED NANOPARTICLES AND METHOD OF MAKING AND USING SAME | THE BOARD OF REGENTS ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF MICHIGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5494683-A | REDUCED TOXICITY, EFFICIENCY | EASTMAN KODAK COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| US-5399363-A | IV administration for insoluble medicaments | EASTMAN KODAK COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0577215-A1 | Surface modified anticancer nanoparticles | NanoSystems L.L.C. (US) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275967-A1 | FREEZE DRIED COMPOSITIONS | TREH, PREP, IL5 | HTT 244/4885DNM1 2709/4885KMT2A 2008/4885 |
| US-12472184-B2 | Dosing regimens associated with extended release paliperidone injectable formulations | DPP3, LPXN, PRLHR | HTT 2872/4885DNM1 1459/4885KMT2A 2947/4885 |
| US-20250161456-A1 | FORMULATION/COMPOSITIONS COMPRISING IBRUTINIB | BTK, BCL6B, SYK | HTT 2260/4885DNM1 4127/4885KMT2A 1664/4885 |
| US-20080279949-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | VEGFA, KDR, FLT1 | HTT 1567/4885DNM1 841/4885KMT2A 4383/4885 |
| US-20260060986-A1 | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations | FKBP3, SNAP23, PPID | HTT 1874/4885DNM1 856/4885KMT2A 2526/4885 |
| US-20250268896-A1 | LIQUID COMPOSITIONS | RNPEP, PREP, IL5 | HTT 450/4885DNM1 3701/4885KMT2A 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.